Diamyd Medical AB (publ) News
Diamyd Gets Authorization to Begin Phase III Study in the US
"We are eager to start this study and to be able to offer this promising drug to our newly diagnosed type 1 diabetes patients", says
"We are extremely pleased with this progress," says
The US Phase III study will enroll 306 new-onset type 1 diabetes patients, who are within 3 months of diagnosis. Results of the study will be analyzed 15 months after all patients have been enrolled. A parallel Phase III study is planned to be conducted in
In a previous Phase II study in young type 1 diabetes patients, Diamyd(R) showed efficacy in preserving the patients' own insulin producing capacity for at least 30 months. No safety concerns have to date been reported in any clinical study with Diamyd(R).
Company website: http://www.diamyd.com
Diamyd Medical AB (publ). Linnegatan 89 B, SE-115 23
Disclaimer: This document contains certain statements relating to the progress, timing and completion of our research, development and clinical trials. These statements can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Diamyd Medical undertakes no obligation to publicly update such statements, whether because of new information, future events or otherwise, nor does Diamyd Medical give any guarantees that the statements, given or implied, are correct. This document is a translation from the Swedish original. No guarantees are made that the translation is free from errors.
SOURCE Diamyd Medical AB (publ)
Search Our News Using Google Search
Can't find what you want? Try using Google:
